Asian Journal of Research in Chemistry

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

A Current Study on Benzimidazole Derivatives


Affiliations
1 Maheshwara Institute of Pharmacy, Chitkul, Isnapur, Patancheru, Hyderabad-502 307 (Andhra Pradesh)
     

   Subscribe/Renew Journal


Benzimidazoles are regarded as a promising class of bioactive heterocyclic compounds that exhibit a wide range of biological activities. Their nucleus is a constituent of vitamin B12 and is present in numerous compounds possessing antioxidant, antiparasitic, anthelmintic, antiproliferative, anti-HIV, anti-allergy, anti-inflammatory, antihypertensive, antineoplastic and antiulcer activity .The present review article is concerned about the heterocyclic chemistry of benzimidazole. Basically it gives emphasis on potential biological activities of benzimidazole derivatives. Benzimidazole is an important lead compound, on modification of the nucleus owing to gives inherent properties and therapeutic action. The present review focuses on the biological activities of the benzimidazoles derivatives reported from 2000 to 2012.

Keywords

Hetero Atom, Pharmacological Activities, Benzimidazole, Anxiolytic , Infections
Subscription Login to verify subscription
User
Notifications
Font Size


  • Palluk R, Hoefke W, Gaida W, Mierau J, Bechtel WD (July 1986). "Interactions of MEN 935 (adimolol), a long acting betaand alpha-adrenolytic antihypertensive agent, with postsynaptic alpha-adrenoceptors in different isolated blood vessels--influence of angiotensin II". Naunyn-Schmiedeberg's Archives of Pharmacology 333 (3): 277–83.

  • Neznamov, GG; Siuniakov, SA; Chumakov, DV; Bochkarev, VK; Seredenin, SB (2001). "Clinical study of the selective anxiolytic agent afobazol". Eksperimental'naia i klinicheskaia farmakologiia 64 (2): 15–9.

  • Rinehart, Kenneth L, et al. (1990). "Bioactive Compounds from Aquatic and Terrestrial Sources". Journal of Natural Products 53 (4): 771–792.

  • Horton J (April 2003). "Albendazole for the treatment of echinococcosis". Fundam Clin Pharmacol 17 (2): 205–12.

  • Matsumoto S, Yamazoe Y (February 2001). "Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine". British Journal of Clinical Pharmacology 51 (2): 133–42

  • Kath R, Blumenstengel K, Fricke HJ, Höffken K (January 2001). "Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia". J. Cancer Res. Clin. Oncol. 127 (1): 48– 54.

  • Ashton, John (August 18, 1996). "Blind Justice: John has no eyes. But now he has hope."

  • Bobon J, Collard J, Lecoq R, Benperidol and promazine: a "double blind" comparative study in mental geriatrics, Acta Neurol Belg. 1963 Oct;63:839-43.

  • Janssen, P. A.; Niemegeers, C. J.; Schellekens, K. H.; Marsboom, R. H.; Herin, V. V.; Amery, W. K.; Admiraal, P. V.; Bosker, J. T. et al. (1971). "Bezitramide (R 4845), a new potent and orally long-acting analgesic compound". Arzneimittel-Forschung 21 (6): 862–867

  • Corcóstegui, R; Labeaga, L; Innerárity, A; Berisa, A; Orjales, A (2005). "Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: Receptor selectivity and in vitro antihistaminic activity". Drugs in R&D 6 (6): 371–84.

  • Pfeffer M, Swedberg K, Granger C, Held P, McMurray J, Michelson E, Olofsson B, Ostergren J, Yusuf S, Pocock S (2003). "Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme". Lancet 362 (9386): 759–66

  • Merck Index, 11th Edition, 1794, 2156.

  • De Cuyper HJ, Van Praag HM, Mulder WR (May 1979). "Therapeutical significance of clopimozide in the treatment of chronic psychotic patients". Acta Psychiatrica Scandinavica 59 (5): 561–74.

  • Lemmon, Mark A.; Schlessinger, Joseph (2010). "Cell Signaling by Receptor Tyrosine Kinases". Cell 141 (7): 1117–1134.

  • Eerenberg, E. S.; Kamphuisen, P. W.; Sijpkens, M. K.; Meijers, J. C.; Buller, H. R.; Levi, M. (2011). "Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects". Circulation 124 (14): 1573–9.

  • Metz, DC; Vakily, M; Dixit, T; Mulford, D (1 May 2009). "Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy". Aliment Pharmacol Ther 29 (9): 928–37

  • Swann IL, Thompson EN, Qureshi K (November 1979). "Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting". British Medical Journal 2 (6199): 1188

  • Peroutka SJ, Synder SH (December 1980). "Relationship of neuroleptic drug effects at brain dopamine, serotonin, alphaadrenergic, and histamine receptors to clinical potency". The American Journal of Psychiatry 137 (12): 1518–22.

  • Somogyi, A; Bochner, F; Foster, D (2004). "Inside the isomers: the tale of chiral switches". Australian Prescriber (National Prescribing Service) 27 (2): 47–9.

  • Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (summer 2002). "Pharmacology of flibanserin". CNS Drug Rev. 8 (2): 117–142

  • Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H, Iwasawa Y. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3- ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). Journal of Medicinal Chemistry. 1999 Dec 16;42(25):5061-3.

  • Sterry W, Assaf C (2007). "Erythroderma". In Bolognia JL. Dermatology. St. Louis: Mosby. p. 154

  • Huckle R. Lerisetron. FAES. Current Opinion in Investigational Drugs. 2003 Jul;4(7):874-7.

  • Luder PJ, Siffert B, Witassek F, Meister F, Bircher J (1986). "Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions". European journal of clinical pharmacology 31 (4): 443–448.

  • Bezprozvanny I, Tsien RW (September 1995). "Voltagedependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9.

  • Mirza NR, Nielsen EØ. Do subtype-selective gammaaminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice? Journal of Pharmacology and Experimental Therapeutics. 2006 Mar;316(3):1378-85.

  • Evenden J, Duncan B, Ko T. A comparison of the effects of psychotomimetics and anxiolytics on punished and unpunished responding maintained by fixed interval schedules of food reinforcement in the rat. Behavioural Pharmacology. 2006 Feb;17(1):87-99

  • Yang YX, Lewis JD, Epstein S, Metz DC (2006). "Long-term proton pump inhibitor therapy and risk of hip fracture". JAMA 296 (24): 2947–2953.

  • Ohmori K, Ishii H, Nito M, Shuto K, Nakamizo N (May 1983). "[Pharmacological studies on oxatomide (KW-4354). (7) Antagonistic effects on chemical mediators]" (in Japanese). Nippon Yakurigaku Zasshi. Folia Pharmacologica Japonica 81 (5): 399–409

  • Pali-Schöll I, Jensen-Jarolim E (April 2011). "Anti-acid medication as a risk factor for food allergy". Allergy 66 (4): 469– 77.

  • Gordon SG, Miller MW, Saunders AB (2006). "Pimobendan in heart failure therapy—a silver bullet?". J Am Anim Hosp Assoc 42 (2): 90–3.

  • Morii M, Takata H, Fujisaki H, Takeguchi N., The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18- 5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor, Biochem. Pharmacol. 1990 Feb 15;39(4):661-7.

  • Fujii Y, Saitoh Y, Tanaka H, Toyooka H (February 2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5

  • Schimke K, Davis TM (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs 8 (4): 338–44

  • Atack JR. Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Current Drug Targets. CNS and Neurological Disorders. 2003 Aug;2(4):213-32.

  • Benson, S. C.; Pershadsingh, H.; Ho, C.; Chittiboyina, A.; Desai, P.; Pravenec, M.; Qi, N.; Wang, J. et al. (2004). "Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist with Selective PPAR -Modulating Activity". Hypertension 43 (5): 993.

  • Upadhyay MP, West EP, Sharma AP (January 1980). "Keratitis due to Aspergillus flavus successfully treated with thiabendazole". Br J Ophthalmol 64 (1): 30–2.

  • Zhang, M; Thurmond, RL; Dunford, PJ (2007). "The histamine H(4) receptor: a novel modulator of inflammatory and immune disorders". Pharmacology & therapeutics 113 (3): 594–606.


Abstract Views: 525

PDF Views: 3




  • A Current Study on Benzimidazole Derivatives

Abstract Views: 525  |  PDF Views: 3

Authors

Y. Dattatri
Maheshwara Institute of Pharmacy, Chitkul, Isnapur, Patancheru, Hyderabad-502 307 (Andhra Pradesh)
P. Divyajyothi
Maheshwara Institute of Pharmacy, Chitkul, Isnapur, Patancheru, Hyderabad-502 307 (Andhra Pradesh)
P. Divyajyothi
Maheshwara Institute of Pharmacy, Chitkul, Isnapur, Patancheru, Hyderabad-502 307 (Andhra Pradesh)
R. Sangeetha
Maheshwara Institute of Pharmacy, Chitkul, Isnapur, Patancheru, Hyderabad-502 307 (Andhra Pradesh)
P. Santosh
Maheshwara Institute of Pharmacy, Chitkul, Isnapur, Patancheru, Hyderabad-502 307 (Andhra Pradesh)

Abstract


Benzimidazoles are regarded as a promising class of bioactive heterocyclic compounds that exhibit a wide range of biological activities. Their nucleus is a constituent of vitamin B12 and is present in numerous compounds possessing antioxidant, antiparasitic, anthelmintic, antiproliferative, anti-HIV, anti-allergy, anti-inflammatory, antihypertensive, antineoplastic and antiulcer activity .The present review article is concerned about the heterocyclic chemistry of benzimidazole. Basically it gives emphasis on potential biological activities of benzimidazole derivatives. Benzimidazole is an important lead compound, on modification of the nucleus owing to gives inherent properties and therapeutic action. The present review focuses on the biological activities of the benzimidazoles derivatives reported from 2000 to 2012.

Keywords


Hetero Atom, Pharmacological Activities, Benzimidazole, Anxiolytic , Infections

References